GenomeQuébec

ANNUAL REPORT 2016-17

Genomics, a vector for the economic development of Québec

TABLE OF CONTENT

ABOUT GÉNOME QUÉBEC

Mission

Génome Québec's mission is to catalyze the development and excellence of genomics research and promote its integration and democratization. The organization contributes to economic development, Québec's influence around the world and the betterment of society.

Vision

Génome Québec is recognized for its assertive leadership in promoting an optimal environment conducive to the development of genomics research and the integration of its benefits into priority sectors for Québec.

Génome Québec prioritizes four strategic sectors: human health, agrifood, forestry and the environment. Here is an overview of the role played by genomics in these sectors, each of which carries tremendous potential for the Québec economy.

MESSAGE FROM THE CHAIR OF THE BOARD

In recent years, we have devoted much energy to strengthening the bonds between universities and industry. In addition to contributing to the growth of genomics, these efforts have helped to position Génome Québec as a key player in the Québec innovation system. I am pleased to report that in this respect the results have been extremely positive. The time has now come, however, to take it to the next level, so that genomics may reach its full potential through its integration into society. Our challenge now revolves around Big Data, deep learning and artificial intelligence.

Let me illustrate my point with the example of the Watson computer system by IBM and its use in medicine. The robot is capable of helping doctors diagnose disease. It can be programmed to process the innumerable files and scientific articles required for establishing patient diagnoses, treatments and prognoses. In the blink of an eye, Watson can analyze and sort through this mass of information, thus serving as an important support tool in decision making.

Sequencing the human genome generates a tremendous volume of data. Unfortunately this information is not much use to doctors unless it is processed and linked with the patient's medical file and family history – hence the need for Watson. Precision medicine will enjoy a successful future only to the extent that we can use the mass of genomic data available based on their environmental and social context. As such, it is critical for each nation to have its own reference genome. The United Kingdom, the United States, China and others are successfully working at this right now. Québec too must jump on the bandwagon, which is why it is hard at work developing a genome reference of 10,000 Quebecers.

I am convinced that this new reality is just around the corner, ready to emerge. As a first clear indication, let us note the federal budget investment in artificial intelligence (Canada First Research Excellence Fund) within major Québec universities. Second, the Québec government's $40 million subsidy to Génome Québec has given us the momentum we need to strengthen our footing. In fact, the Québec life science strategy has identified precision medicine and Big Data analytics for health care as two cross-cutting niches to be prioritized in order to position Québec as a global innovation leader.

For Génome Québec, the meeting of these two sectors of excellence – artificial intelligence and genomics – will help Québec attain a unique position on the world stage, attract foreign investments and transfer, at a faster pace, the benefits of promising breakthroughs to Quebecers.

To meet these ambitious, yet realistic, goals, we have brought on board a seasoned leader. I would like to warmly welcome to Génome Québec our new President and CEO, Daniel Coderre, a man recognized for his reputation as an excellent manager.

Last but not least, I wish to thank the members of the Board of Directors for their outstanding contribution in bringing their experience in the field, their expertise and exceptional energy to our organization.

MARTIN GODBOUT

MESSAGE FROM THE PRESIDENT AND CEO

This year was marked by major achievements for our organization: $40 million in funding from the provincial government, exceptional results from Québec researchers in Genome Canada competitions, outstanding performance of the Innovation Centre and, last but not least, the arrival of a new Vice President of Scientific Affairs from the field of bioinformatics.

Over the past 17 years, Génome Québec, whose mission is to serve as a catalyst for the development and competitiveness of genomics research in Québec, has consistently demonstrated its ability to support the growth of this technology in both university and private sector settings. The results generated by our activities have, without a doubt, helped to establish an enviable critical mass.

Reaching this milestone, however, could only have been achieved with a solid research support strategy and an exceptional financing model based on a spirit of partnership. Through the cooperation of researchers, users, co-funders and the various levels of government, we have been able to remain at the cutting edge of the rapidly evolving genomics science and stay abreast of the opportunities in our strategic sectors.

Our business model and operational flexibility are key factors of this success, since this is how we are able to attract the private sector and partners/users. For every dollar invested in Génome Québec by the provincial government, more than two additional dollars from outside sources are injected into the development of genomics here at home.

After investments of close to $1 billion in genomics since 2001 – with $283 million coming from the Québec government – we now have at our disposal first-rate expertise and infrastructures, providing us with a competitive edge to stand out among the world's best.

To successfully achieve the integration of this disruptive technology by users and confirm our ability to compete globally, we must nevertheless ensure the long-term sustainability of our investments in research. In this respect, we recognize the vital support of the provincial government, whose latest budget included $40 million in funding for our organization. It sends a clear message about the role of genomics as a vehicle for innovation and economic prosperity in Québec. We will be pursuing our efforts in our four promising strategic sectors: precision medicine, agrifood, forestry and the environment (sustainable development and climate change). These application niches for genomics hold tremendous potential for the Québec economy, particularly since many of the industries that stand to benefit are firmly embedded in the province's industrial fabric.

None of this would be possible, of course, without the capable and dedicated members of our team. As such, I would like to welcome on board Francis Ouellette as Vice President of Scientific Affairs. Recognized for his in-depth knowledge of bioinformatics issues, he is a key asset for responding to the major challenge that lies ahead in terms of the storage, interpretation and optimal use of Big Data generated by genomics in its strategic sectors.

Last, I would like to acknowledge our employees whose competence and ingenuity propel us towards the successful outcome of this great adventure to make genomics a lever of economic and social development for a prosperous, innovative society.

DANIEL CODERRE

2016-2017 HIGHLIGHTS

$40 MILLION

Provincial Budget: Record funding for Génome Québec with $40 million from the provincial government

GOVERNANCE

Daniel Coderre takes the helm of Génome Québec as President and CEO in September 2016

SCIENTIFIC AFFAIRS

Bioinformatics expert Francis Ouellette joins the team as Vice President of Scientific Affairs in January 2017

RESEARCH BUDGET

The funding from Genome Canada awarded to Québec for new projects doubled since last year: from $17 million to $35 million

COMPETITIONS

- 18 new projects funded
- Québec excels in Genome Canada competition on natural resources by securing nearly 34% of the federal co-funding available

SERVICE EXCELLENCE

The McGill University and Génome Québec Innovation Centre: 972 research teams served. Client satisfaction rate of 95%

SCIENTIFIC OUTREACH

Now having reached maturity, genomics has become a vehicle for progress and a generator of solutions. This powerful disruptive technology is funded in a way that promotes the transfer of research results to a variety of sectors in order to maximize their social and economic impact.

Each year, the Scientific Affairs team supports a growing number of researchers with the express goal of positioning them among the best in Québec and Canada. This requires a solid expertise in several areas of activity.

Great performance while managing twice the funding envelope

This year, we oversaw the launch of five new competitions in:

- Natural resources and the environment
- Genomic Application Partnership Program (GAPP)
- Genomic Disruptive Innovation
- Bioinformatics and computational biology
- Development of technology platforms

Despite limited resources, our team successfully managed 66 research teams and twice the overall genomics research budget of last year. This significant increase is proof of the competitiveness of Québec researchers and points to the importance of providing them with quality support throughout the competition process. In addition, a networking event that brought together researchers and members of the life science industry was organized in March to promote partnerships between universities and the private sector as part of the Genome Canada competition in precision medicine. The event attracted over 130 people and generated nearly 160 meetings. Initiatives such as these are crucial, since they play a critical role in fostering academia-industry collaborations.

New researchers this year included Sébastien Sauvé and his team at Université de Montréal, Niladri Basu of McGill University, Éric Lécuyer of the Montreal Clinical Research Institute (IRCM) and Claude Robert of Université Laval.

The Scientific Affairs team also ensured the follow-up of a portfolio of 64 active projects this year, including the management of research oversight committees with more than 50 international experts.

Announcement of Genome Canada Natural Resources and the Environment competition. Photo, from left to right: Sébastien Sauvé, Université de Montréal – Dominique Anglade, ministre de l'Économie, de la Science et de l'Innovation du Québec - Kirsty Duncan, Canada Minister of Science

FUNDING OF NEW PROJECTS ANNUAL COMPARISON	15-16	16-17
Total Budget	$42,5 M	$ 85 M
Number of projects supported	47	66
Number of projects funded	17	18
Genome Canada funding awarded in Québec	$17 M	$34,9 M
Total Genome Canada funding available in Canada	$61,4 M	$123 M
Annual success rate (%) in Québec	28 %	28,4 %
Number of active projects in the portfolio	51	64

Supporting the integration of breakthrough technologies

By taking a step back, we can see a pattern emerge from this year's competitions: they have converged on the development and integration of cutting-edge technologies in genomics, the use of bioinformatics and the creation of technology platforms. The success of Québec research teams in these competitions has been essential since it promotes access to high-performance genomic technologies and gives the scientific community the tools it needs to overcome the challenges generated by Big Data, among others. Gaining a foothold in the digital era means that Génome Québec must have at its disposal powerful technologies that can grasp all of the intricacies of biological phenomena and make significant improvements to the quality of life of our community. Our organization will continue to promote cooperative efforts between the bioinformatics and computational biological experts in Québec, while, of course, focusing on our four strategic sectors: precision medicine, agrifood, forestry and the environment.

Announcement of Genome Canada Genomics Disruptive Innovation Competition. Photo, from left to right:
Mathieu Blanchette, McGill University
Jérôme Waldispühl, McGill University
Santiago Costantino, Hôpital Maisonneuve-Rosemont
Daniel Coderre, Génome Québec
Marc Miller, Government of Canada
Éric Lécuyer, IRCM – Tarik Möröi, IRCM,
Marc LePage, Genome Canada

TECHNOLOGICAL OUTREACH

Génome Québec operates three technology platforms:

- McGill University and Génome Québec Innovation Centre
- CHU Sainte-Justine and Génome Québec Integrated Pediatric Clinical Genomics Centre
- Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank.

These platforms provide a range of services to the scientific community and to industry, including genotyping, gene sequencing, gene expression, epigenomics, bioinformatics and biobanks.

In addition, Génome Québec coordinates access to the population-based longitudinal cohort of CARTaGENE, and to the clinical cohorts of the Genizon Biobank, the Canadian Centre for Computational Genomics (C3G) and the Centre for Advanced Proteomics Analyses (CAPA).

2016-2017 Highlights

The McGill University and Génome Québec Innovation Centre pursued its mission of providing support to the national and international research community. It served 972 teams of researchers, for an increase of 8 percent compared to 2015-2016.



The Centre recorded revenues of $16 million – with $2.3 million coming from international clients (14%). The user satisfaction rate of 95% across the board is indicative of the level of excellence in the services offered.

The CHU Sainte-Justine and Génome Québec Integrated Pediatric Clinical Genomics Centre continued to work on securing accreditation to provide Quebecers with clinical sequencing services.

Génome Québec and the Centre hospitalier affilié universitaire régional de Chicoutimi Biobank secured major DNA extraction contracts, primarily from CARTaGENE.

DEVELOPMENT BY SECTOR AND PUBLIC OUTREACH

One of the main challenges of genomics consists in getting its results out of the lab and into society. For this to happen, we need to design activities that can both mobilize stakeholders and lead to the development of new tools.

Integrating genomics into its various areas of application (human health, agrifood, forestry and the environment) entails a major shift in our way of doing things. Consequently, the appropriation by users of this disruptive technology requires substantive work to inform, train and reassure the different constituencies involved.

Young people form one such constituency. We firmly believe in the need to start from the ground up. For this reason, we are working on introducing genomics into schools and engaging youth in science as a way of preparing the next generation of scientists.

Here are some of the initiatives we have launched in the past year:

Mobilization and Education

- Vol450 Mini-Lab: A portable mini-lab and learning situation developed by the Commission scolaire de Laval in partnership with Génome Québec, the McGill University and Génome Québec Innovation Centre and the Commission scolaire de la Seigneurie-des-Mille-Îles. Through the mini-lab, students are able to launch a scientific investigation and work with DNA. To date, the kit has been loaned to over 15 schools and more than 800 students have taken part in the experiment.



- L'ADN à l'Assemblée nationale: 11 teams of researchers representing Génome Québec's four strategic sectors took part in the event as ambassadors for genomics, where they met with members of the National Assembly and cabinet ministers from all political parties. The high turnout proves the importance of holding such events.

Health/Life Science

- Strategic partnership with the Chamber of Commerce of Metropolitan Montreal to position the life science sector as an economic lever for the business community (forum, targeted meetings, participation in various discussion panels, etc.)
- Organization of a conference during the Québec City Healthcare Industry Forum. The activity focused on benefits for patients in keeping with the theme of "integrating technology into the healthcare system."

- Participation in a public conference (Carrefour en santé personnalisée) focusing on breast cancer, personalized medicine and the role of patients and doctors. Organized as part of the International Congress on Personalized Health Care in partnership with the Québec Breast Cancer Foundation.

- During BIO 2016, hosting of a discussion panel on the theme of Genomics in clinical practice and opportunities for biotech – How can Québec leverage international success? Forty people attended the activity, along with the Minister of Economy, Science and Innovation and the Chief Scientific Officer.

Agrifood and food safety

- Partnership with the Institute of Nutrition and Functional Foods (INAF) of Université Laval and BÉNÉFIQ (a biennial rendezvous on health ingredients) for the satellite symposium of the Quebec Association for Food Protection (AQIA).

The environment and sustainable development

- Partnerships with Écotech Québec (cleantech cluster) and the Conseil des entreprises en technologies environnementales du Québec (CETEQ)

The environment – Climate change

- Publication of a story by Marie-Claude Malboeuf on genomics and climate change published in La Presse+ in November 2016.

COMING CHALLENGES

For genomics to succeed, it must be adopted by the population. Without public support, no one will be able to reap the benefits from the funds that have been invested in genomics for more than 17 years. This is why we must focus on education, training and skills development. Ultimately, citizens are the ones who must enjoy the spinoffs of genomics. As such, in the coming year, we will be pursuing efforts to stimulate people's interest in science and innovation and develop the ability of citizens and institutions to engage in decision making using scientific knowledge.

FINANCIAL ACTIVITY REPORT

Génome Québec receives most of its financial support from the Québec government and Genome Canada for the funding of research projects and the operation of its technology centres.

As of March 31, 2017, our research portfolio includes 58 research projects, while three technology centres are currently in operation. Génome Québec invested $52.3 million during the 2016-2017 fiscal year. This amount, combined with the $36.1 million invested by other partners, brings our overall injection of funds to $88.4 million, an increase of 2.8% over last year.

Business volume generated by research projects during this fiscal year amounted to $64.8 million. The most important activities are from the Genomics and Personalized Health competition and the Fonds de partenariat pour un Québec innovant et en santé. This year, new projects from the Natural Resources and the Environment, the Disruptive Innovation in Genomics and the Bioinformatics and Computational Biology competitions were launched. The budget for projects underway totals $349 million, $113 million of which is still to be carried out.

For the year ended on March 31, 2017, sales arising from the technology centres totalled $16.5 million, down 3.9% compared to last year. However, the technology centres posted an excess of revenues over expenses of $685,373 compared to an insufficiency of $555,351 from the previous fiscal year.

General and administrative expenses, business development and communications and committee expenses amounted to $2.9 million, a decrease of $570,382 compared to last fiscal year. After certain adjustments, these expenses represent 3.3% of total investments for the year. Investment and intellectual property revenues reached $162,326, for a return of 1.16%.

The excess of revenue over expenses totalling $687,700 is the combined effect of the surplus of $685,373 generated by the technology centres, the investment and intellectual property revenues of $162,326 dollars, minus the insufficiency resulting from the general and administrative expenses of $158,806, and from activities carried out without government funding of $1,193. Non-designated net assets were up $626,439, reaching a total of $2.7 million on March 31, 2017. Net assets dedicated to activities decreased by $145,905 during the fiscal year and represent a net balance of $74,587. Net assets totalling $735,096 have once again been earmarked for the contingency and technological development funds.

Finally, Génome Québec has respected the terms and conditions in compliance with the contractual agreements it has signed with its major financial partners.

DANIEL CODERRE
PRESIDENT AND CEO,
GÉNOME QUÉBEC

CLAUDE LAMARRE
VICE PRESIDENT, FINANCE
GÉNOME QUÉBEC

FINANCIAL STATEMENTS

Statements of financial position - March 31, 2017 with comparative information for 2016

The Statements of Financial Position as at March 31, 2017 and 2016, and the Statement of Operations for the years ended March 31, 2017 and 2016 that follow are provided as illustrative summaries only are are not intended to replace the full financial statements of Génome Québec. These full financial statements, available in French only, were audited by KPMG s.r.l./S.E.N.C.R.L., Chartered Professional Accountants, and reported on June 13, 2017.

	2017	2016
ASSET		
CURRENT ASSETS		
Cash and cash equivalents	$41,431,851	$703,969
Short-term investments	12,347,946	5,134,021
Contributions receivable	-	3,841,417
Accounts receivable and work in progress	4,365,069	2,116,882
Advances to genomics research projects	7,606,302	5,781,786
Inventories	2,126,461	2,121,909
Prepaid expenses	126,256	145,611
	$68,003,885	**$19,845,595**
Long-term investments	-	3,264,946
Capital assets	393,582	532,541
	$68,397,467	**$23,643,082**
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES		
Accounts payable and accrued liabilities	$3,757,975	$5,930,343
Obligations related to an agreement	351,076	334,384
	$4,109,051	**$6,264,727**
DEFERRED CONTRIBUTIONS		
Future expenses	60,387,129	14,053,739
Capital assets	381,470	492,499
	$60,768,599	**$14,546,238**
	$64,877,650	**$20,810,965**
NET ASSETS		
Unrestricted	2,698,022	2,071,583
Restricted - Invested in capital assets	12,112	40,042
Restricted - Technology investment and contingency fund	735,096	500,000
Restricted - Research projects	74,587	220,492
	3,519,817	**2,832,117**
	$68,397,467 $	**$23,643,082 $**

STATEMENT OF OPERATIONS - Year ended March 31, 2017 with 2016 comparative information

	2017	2016
REVENUES		
Amortization of deferred contributions related to expenses	$37,694,787	$40,423,630
Amortization of deferred contributions related to capital assets	215,572	219,418
Investment and intellectual property revenues	162,326	166,629
Revenues from technology centres	16,545,317	17,212,977
Other revenues	451,035	645,621
	55 069 037	58,668,275
EXPENSES		
Genomics research projects	16,913,187	21,770,354
Research projects, Québec Innovant et en Santé	13,885,311	12,501,215
Technology centres operational costs	20,461,899	21,950,950
General and administrative expenses	2,587,338	2,955,797
General and administrative expenses, Québec Innovant et en santé	128,632	131,050
Business development and communications	147,559	300,919
Committees	13,909	60,054
Depreciatin of capital assets	215,572	219,418
Depreciation of restricted capital assets	27,930	36,560
	54,381,337	59,926,317
Excess (Insufficiency) of revenues over expenses	**$687,700**	**$ (1,258,042)**

BOARD OF DIRECTORS, COMMITTEES AND EMPLOYEES

BOARD OF DIRECTORS

Martin Godbout, O.C., PhD
CHAIR OF THE BOARD

Paule Têtu, F.Eng., MSc
VICE CHAIRMAN OF THE BOARD

Me Jean Brunet
SECRETARY OF THE BOARD
Managing Partner, Stein Monast L.L.P.

BOARD MEMBERS

Daniel Coderre, PhD
President and CEO, Génome Québec

Sophie D'Amours, Eng., PhD

Hélène Desmarais, C.M., LL.D.
CEO and Chair of the Board of Administration, Centre d'entreprises et d'innovation de Montréal

Marie-Lucie Morin

Anie Perrault, LL.L., ASC
Executive Manager, BIOQuébec

Rémi Quirion, PhD, CQ, O.C., FRSC
Chief Scientist of Québec, Fonds de recherche du Québec (FRQ)

François R. Roy
Corporate Director

Suzanne Vinet

Brian White-Guay, MD, FRCPC
Professor, Faculty of Pharmacy, Université de Montréal

OBSERVERS

Marie-Josée Blais, PhD
Assistant Deputy Minister for Innovation, ministère de l'Économie, de la Science et de l'Innovation

Marc LePage
President and CEO, Genome Canada

FINANCE COMMITTEE

François R. Roy
COMMITTEE CHAIR

Anie Perrault, LL.L., ASC

Brian White-Guay, MD, FRCPC

GOVERNANCE, NOMINATION AND HUMAN RESOURCES COMMITTEE

Martin Godbout, O. C., PhD
COMMITTEE CHAIR

Jean Brunet, Attorney
SECRETERAY OF THE COMMITTEE

Daniel Coderre, PhD
Sophie D'Amours, Eng., PhD
Marie-Lucie Morin
Paule Têtu, F.Eng., MSc
Suzanne Vinet

COMITÉ EXÉCUTIF

Martin Godbout, PhD
COMMITTEE CHAIR

Me Jean Brunet
SECRETERAY OF THE COMMITTEE

Daniel Coderre, PhD

Marie-Lucie Morin

Paule Têtu, F.Eng., MSc

MANAGEMENT COMMITTEE

Daniel Coderre
President and CEO

Marie-Kym Brisson
Vice President, Business Development, Partnerships and Communications

Claude Lamarre
Vice President, Finance

Francis Ouellette
Vice President, Scientific Affairs

Daniel Tessier
Vice President, Technology Centres

STRATEGIC AND SCIENTIFIC ADVISORY BOARD (SSAB)

Louise Proulx, PhD
COMMITTEE CHAIR
Therilia inc., Canada

Martine Dubuc, DMV
Agence canadienne d'inspection des aliments (ACIA), Canada

Michel Goldman, PhD
Université libre de Bruxelles, Belgium

Karl (Chuck) Hasel, PhD MBA
Hasel Consulting, United States

Antoine Kremer, PhD
Institut national de la recherche agronomique (INRA), France

Teri Manolio, MD, PhD
National Human Genome Research Institute (NHGRI), United States

Mark McCarthy, PhD
Wellcome Trust, United Kingdom

Michael Müller, PhD
Norwich Research Park Food and Health Alliance (FAHA), United Kingdom

ADMINISTRATIVE CENTRE

Micheline Ayoub
Line Benguerel
Diane Bouchard
Marie-Kym Brisson
Cristina Ciurli
Daniel Coderre
Hélène Fournier
Nathaly Hébert
Diana Iglesias
Éva Kammer
Claude Lamarre
Fabienne Lefebvre
Darie Lessard
Francis Ouellette
Nidia Salazar
Ève-Stéphanie Sauvé
Joël Savard
Annina Spilker
Louise Thibault
Vincent Trudel

BIOBANK

Steve Arsenault

TECHNOLOGY CENTRES

Vicky Arsenault
François-Marie Bacot
Julie Boudreau
Geneviève Bourret
Sébastien Brunet
Valérie Catudal
Geneviève Dancausse
Philippe Daoust
Geneviève Donpierre
Nathalie Émond
Joëlle Fontaine
Nicolas Fréchette
Rosalie Fréchette
Geneviève Geneau
Philippe Gingras Gélinas
Isabelle Guillet
Nathalie Hamel
François Korbuly
Sylvie LaBoissière
Pierre Lepage
François Massé
Marc Michaud
Jana Mickova
Alexandre Montpetit
Frédérick Robidoux
Sharen Sophie Roland
Janick St-Cyr
Daniel Tessier
Annie Verville
Daniel Vincent
Hoai-Thu Vo
Patrick Willett
Hao Fan Yam
Corine Zotti

CHU STE-JUSTINE

René Allard
Virginie Saillour

FONDS DE PARTENARIAT POUR UN QUÉBEC INNOVANT ET EN SANTÉ (FPQIS)

Marie-Paule Choquette
Stéphanie Lord-Fontaine
Julie Vallée
Tu Linh Van

LARGE-SCALE PROJECT OUTCOMES

GENOMIC APPLICATION PARTNERSHIP PROGRAM (GAPP)
April 1, 2016 - December 31, 2016

	NUMBER OF PERSONS EMPLOYED 2016-2017 *(person-years)*	NUMBER OF SCIENTISTS TRAINED 2016-2017 *(person-years)*	NUMBER OF PUBLICATIONS ACCEPTED 2016-2017	NUMBER OF CONFERENCES AS SPEAKER 2016-2017	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS 2016-2017	PROJECT STARTING DATE
STEVE LABRIE- ULAVAL *Metagenomics and cheesemaking technologies*	1.46	0	0	0	0	APRIL 2014
ADRIAN TSANG - UCONCORDIA *Enzyme supplement for swine and poultry*	12.09	0	0	0	0	OCTOBER 2014
HAMELIN - UCOLOMBIE-BRITANNIQUE / ROGER C. LÉVESQUE - ULAVAL *Next generation biosurveillance of invasive alien species*	0.41	0	1	2	0	OCTOBER 2014
JEAN BOUSQUET - ULAVAL *FastTRAC (fast tests for rating and amelioration of conifers)*	7.64	0.32	1	8	0	APRIL 2015
MICHEL BERGERON - CHU DE QUÉBEC *Nouveau test pour le diagnostic rapide des infections*	5.97	0	1	4	0	OCTOBER 2015
CHRISTOPH BORCHERS - HÔPITAL GÉNÉRAL JUIF *New test to rapidly diagnose infections*	6.22	2.26	0	13	0	APRIL 2016
CHARLES GOULET - ULAVAL *A genetic toolbox for tomato flavour differentiation*	1.89	0.98	-	-	-	APRIL 2016
PIERRE THIBAULT - UMONTRÉAL *Mass spectrometry improvement for personalized medicine*	0.98	0.25	1	0	0	OCTOBER 2016
CLAUDE ROBERT - ULAVAL *Improve swine genetics*	1.21	0	0	0	0	OCTOBER 2016
TOTAL	37.87	3.81	4	27	0	

2015 COMPETITION: LARGE-SCALE RESEARCH PROJECTS - NATURAL RESOURCES AND THE ENVIRONMENT- SECTOR CHALLENGES - GENOMIC SOLUTIONS

	NUMBER OF PERSONS EMPLOYED 2016-2017 (person-years)	NUMBER OF SCIENTISTS TRAINED 2016-2017 (person-years)	NUMBER OF PUBLICATIONS ACCEPTED 2016-2017	NUMBER OF CONFERENCES AS SPEAKER 2016-2017	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS 2016-2017	PROJECT STARTING DATE
SÉBASTIEN SAUVÉ - UMONTRÉAL *Algal blooms, treatment, risk assessment, prediction and prevention through genomics*	12.78	3.23	1	13	0	OCTOBER 2016
NILADRI BASU - MCGILL *Development of a toxicogenomics analysis tool*	5.53	2.30	0	0	0	OCTOBER 2016
BOHLMANN - UBC / BOUSQUET - ULAVAL *Spruce-Up (advanced spruce genomics)*	4.56	0.49	3	0	0	OCTOBER 2016
HAMELIN - UCOLOMBIE-BRITANNIQUE / PORTH - ULAVAL *BioSAFE (BioSurveillance of Alien Forest Enemies)*	4.92	1.50	0	1	0	OCTOBER 2016
AITKEN - UCOLOMBIE-BRITANNIQUE / HAMELIN - ULAVAL *CoAdapTree (healthy trees for future climates)*	0.25	0	0	0	0	OCTOBER 2016
WARREN - UTORONTO / BARON - UMONTRÉAL *Next generation biological treatment of mining waste-waters*	0.30	0	-	-	0	OCTOBER 2016
HUBERT - UCALGARY / GREER - MCGILL *Microbial genomics for oil spill preparedness in Canada's Arctic marine environment*	0.11	0	0	0	0	OCTOBER 2016
MASTER - UTORONTO / TSANG - UCONCORDIA *SYNBIOMICS (advanced biopolymer synthesis)*	Start of the project: no data available					JANUARY 2017
TOTAL	28.45	7.52	4	14	0	

2015 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY COMPETITION

	NUMBER OF PERSONS EMPLOYED 2016-2017 (person-years)	NUMBER OF SCIENTISTS TRAINED 2016-2017 (person-years)	NUMBER OF PUBLICATIONS ACCEPTED 2016-2017	NUMBER OF CONFERENCES AS SPEAKER 2016-2017	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS 2016-2017	PROJECT STARTING DATE
FRANÇOIS MAJOR - UMONTRÉAL *Development of RNAi-based therapeutics agents*	Data available in October 2017					OCTOBER 2016
JESSE SHAPIRO - UMONTRÉAL *Toolkit for genome-wide association studies in bacteria*						OCTOBER 2016
JÉRÔME WALDISPÜHL - MCGILL *Identification of small RNA-binding molecules regulating gene expression*						OCTOBER 2016
JÉRÔME WALDISPÜHL - MCGILL *Crowdsourcing genomic databases*						OCTOBER 2016
TOTAL	-	-	-	-	-	

2015 DISRUPTIVE INNOVATION IN GENOMICS (DIG) COMPETITION

	NUMBER OF PERSONS EMPLOYED 2016-2017 *(person-years)*	NUMBER OF SCIENTISTS TRAINED 2016-2017 *(person-years)*	NUMBER OF PUBLICATIONS ACCEPTED 2016-2017	NUMBER OF CONFERENCES AS SPEAKER 2016-2017	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS 2016-2017	PROJECT STARTING DATE
PHASE 1						
SANTIAGO COSTANTINO - HÔPITAL MAISONNEUVE-ROSEMONT *Laser assisted single-cell genomics*	Data available in July 2017					JULY 2016
DAVID JUNKER - MCGILL *Single exosome multi-omic analysis*						JULY 2016
ÉRIC LÉCUYER - IRCM *RNA zipcode discovery pipeline*						JULY 2016
MARK TRIFIRO - HÔPITAL GÉNÉRAL JUIF *Rapid diagnostics through plasmonic PCR*						JULY 2016
MICHAEL TYERS - UMONTRÉAL *Cell microfactory platform*						JULY 2016
PHASE 2						
SACHDEV SIDHU - UTORONTO / EL BACHIR AFFAR - HÔPITAL MAISON-NEUVE-ROSEMONT *Synthetic inhibitors of ubiquitin-binding cancer targets*	2.82	0	0	0	0	JULY 2016
TOTAL	2.82	0	0	0	0	

2014 GENOMICS AND FEEDING THE FUTURE COMPETITION:

	NUMBER OF PERSONS EMPLOYED 2016-2017 *(person-years)*	NUMBER OF SCIENTISTS TRAINED 2016-2017 *(person-years)*	NUMBER OF PUBLICATIONS ACCEPTED 2016-2017	NUMBER OF CONFERENCES AS SPEAKER 2016-2017	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS 2016-2017	PROJECT STARTING DATE
FRANÇOIS BELZILE - ULAVAL *Improving yield and disease resistance in short-season soybean (SoyaGen)*	22.87	8.58	0	10	0	OCTOBER 2015
LAWRENCE GOODRIDGE - MCGILL / ROGER C. LEVESQUE - ULAVAL *Ensure food safety and reduce the economic burden of salmonellosis*	22.73	4.30	0	15	0	OCTOBER 2015
FOSTER - UCOLOMBIE-BRITANNIQUE / NICOLAS DEROME - ULAVAL *Sustaining and securing Canada's honey bees using 'omic' tools*	2.90	0.25	0	0	0	OCTOBER 2015
DAVIDSON - UCOLOMBIE-BRITANNIQUE / LOUIS BERNATCHEZ - ULAVAL *Enhancing production in Coho: culture, community, catch (EPIC4)*	5.98	0	0	3	0	OCTOBER 2015
TOTAL	54.48	13.13	0	28	0	

SHARING BIG DATA FOR HEALTH CARE INNOVATION: ADVANCING THE OBJECTIVES OF THE GLOBAL ALLIANCE FOR GENOMICS AND HEALTH

	NOMBRE DE PERSONNES EMPLOYÉES 2016-2017 *(année-personne)*	NOMBRE DE CHERCHEURS FORMÉS 2016-2017 *(année-personne)*	NOMBRE DE PUBLICATIONS ACCEPTÉES 2016-2017	NOMBRE DE CONFÉRENCES À TITRE DE CONFÉRENCIER 2016-2017	NOMBRE DE DÉCLARATIONS D'INVENTIONS OU DE BREVETS 2016-2017	DATE DE DÉBUT DU PROJET
BARTHA KNOPPERS - P3G *Canadian international data sharing initiative to accelerate health care innovation (Can-SHARE)*	16.07	1.31	7	6	0	JUNE 2015
TOTAL	16.07	1.31	7	6	0	

GENOMICS INNOVATION NETWORK COMPETITION

	NUMBER OF PERSONS EMPLOYED 2016-2017 *(person-years)*	NUMBER OF SCIENTISTS TRAINED 2016-2017 *(person-years)*	NUMBER OF PUBLICATIONS ACCEPTED 2016-2017	NUMBER OF CONFERENCES AS SPEAKER 2016-2017	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS 2016-2017	PROJECT STARTING DATE
CORE OPERATION SUPPORT						
PHILIP AWADALLA - CHU STE-JUSTINE *Canadian Data Integration Centre (CDIC)*	6.08	0	6	7	0	APRIL 2015
GUILLAUME BOURQUE - MCGILL *Canadian Centre for Computational Genomics (C3G)*	15.87	0	12	10	0	APRIL 2015
MARK LATHROP - MCGILL *McGill University and Génome Québec Innovation Centre*	45.53	0	0	0	0	APRIL 2015
PIERRE THIBAULT - UMONTRÉAL *Centre for Advanced Proteomic Analyses (CAPA)*	7.65	0	21	19	1	APRIL 2015
TECHNOLOGY						
GUILLAUME BOURQUE - MCGILL *Canadian Centre for Computational Genomics (C3G)*	2.13	0	3	1	0	OCTOBER
MARK LATHROP - MCGILL *McGill University and Génome Québec Innovation Centre*	9.29	0	5	0	0	OCTOBER 2015
TOTAL	86.55	0	47	37	1	

COMPETITION: FONDS DE PARTENARIAT POUR UN QUÉBEC INNOVANT ET EN SANTÉ

	NUMBER OF PERSONS EMPLOYED 2016-2017 (person-years)	NUMBER OF SCIENTISTS TRAINED 2016-2017 (person-years)	NUMBER OF PUBLICATIONS ACCEPTED 2016-2017	NUMBER OF CONFERENCES AS SPEAKER 2016-2017	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS 2016-2017	PROJECT STARTING DATE
GERALD BATIST - HÔPITAL GÉNÉRAL JUIF *Personalized health care network Q-CROC*	34.17	0	1	6	0	APRIL 2014
MICHEL BERGERON - CHU DE QUÉBEC *Rapid molecular diagnosis of infections (C Diff, BMDR)*	15.85	0	0	0	0	APRIL 2014
MICHEL BOUVIER - UMONTRÉAL *Drug discovery*	59.07	4.15	4	13	3	APRIL 2014
NICOLA HAGEMEISTER - ÉTS *Improve diagnosis and treatment for arthritis of the knee*	9.09	1.00	1	0	0	OCTOBER 2014
PAVEL HAMET - CHUM *OPTI-THERA- Optimization of the therapeutic approaches in primary care*	Completed project					APRIL 2014
JEAN-CLAUDE TARDIF- ICM *ARTERIA- Cardiovascular personalized diagnostics and therapies*	66.03	0.90	12	2	1	APRIL 2014
BRIAN WARD- CUSM *Development of vaccines against pneumonia using plants*	21.87	7.56	3	7	0	APRIL 2014
TOTAL	206.08	13.61	21	28	4	

2012 GENOMICS AND PERSONALIZED HEALTH COMPETITION

	NUMBER OF PERSONS EMPLOYED 2016-2017 (person-years)	NUMBER OF SCIENTISTS TRAINED 2016-2017 (person-years)	NUMBER OF PUBLICATIONS ACCEPTED 2016-2017	NUMBER OF CONFERENCES AS SPEAKER 2016-2017	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS 2016-2017	PROJECT STARTING DATE
MIKE TYERS - UMONTRÉAL *Biological network in human health*	9.00	0	10	7	0	APRIL 2011
TOTAL	9.00	0	10	7	0	

2012 GENOMICS AND PERSONALIZED HEALTH COMPETITION

	NUMBER OF PERSONS EMPLOYED 2016-2017 *(person-years)*	NUMBER OF SCIENTISTS TRAINED 2016-2017 *(person-years)*	NUMBER OF PUBLICATIONS ACCEPTED 2016-2017	NUMBER OF CONFERENCES AS SPEAKER 2016-2017	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS 2016-2017	PROJECT STARTING DATE
CLAUDE PERREAULT - HÔPTAL MAISONNEUVE-ROSEMONT *Immunotherapy (cancer)*	8.08	1.00	0	1	0	APRIL 2013
PATRICK COSSETTE - CHUM *Epilepsy*	11.60	0	2	0	0	APRIL 2013
GUY SAUVAGEAU - UMONTRÉAL *Leucégène (innovative chemogenomic tool for acute myeloid leukemia)*	24.64	1.75	3	8	1	APRIL 2013
FRANÇOIS ROUSSEAU - ULAVAL *ULaval • PEGASUS (Prenatal aneuploidy Àscreening using maternal blood)*	22.62	5.23	9	29	0	APRIL 2013
JACQUES SIMARD - ULAVAL *Breast cancer (Prevention and early detection)*	22.28	5.08	10	9	0	APRIL 2013
JOHN RIOUX - ICM *iGenomed (Inflammatory bowel diseases)*	22.46	2.50	1	6	0	APRIL 2013
JEAN-CLAUDE TARDIF - ICM *Cardiovascular disease (Targeted therapeutics)*	11.06	2.50	5	6	1	APRIL 2013
NADA JABADO - INSTITUT DE RECHERCHE DU CUSM *iChange (Pediatric brain cancer)*	17.28	7.83	15	30	0	APRIL 2013
SIN - UCOLOMBIE-BRITANNIQUE / MAC-NAMARA, BOURBEAU - MCGILL / AWA-DALLA - UMONTRÉAL / MALTAIS - ULAVAL *COPD (disease management)*	1.40	0	0	0	0	APRIL 2013
HARRIGAN - UCOLOMBIE-BRITANNIQUE / CHAREST, TREMBLAY - INSPQ / ROGER - UMONTRÉAL / WAINBERG - MCGILL *AIDS (response to therapies)*	0.75	0	1	0	0	APRIL 2013
MCCABE - UALBERTA / GOLD, KIMMELMAN - MCGILL *PACE-'Omics (GE3LS, adoption of personalized medicine)*	2.93	0	3	9	0	APRIL 2013
BOYCOTT - UOTTAWA / BRAIS, KNOPPERS, MAJEWSKI - MCGILL / MICHAUD, SAMUELS - CHU SAINTE-JUSTINE *CARE for RARE (Rare Genetics Diseases in Canada)*	2.64	0	21	0	0	APRIL 2013
TOTAL	147.74	25.89	70	98	2	
TOTAL ONGOING PROJECTS	589	65	163	245	7	

ASSESSMENT OF COMPLETED PROJECTS

	NUMBER OF PERSONS EMPLOYED *(person-years*	NUMBER OF SCIENTISTS TRAINED *(person-years)*	NUMBER OF PUBLICATIONS ACCEPTED	NUMBER OF CONFERENCES AS SPEAKER	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS	DURATION OF THE PROJECT
GÉNOME QUÉBEC RECRUITMENT PROGRAM						
CARTaGENE DIRECTOR						
PHILIP AWADALLA - CHU STE-JUSTINE *CARTaGENE*	**65.17**	**0**	**53**	**42**	**0**	**5 years**
HUMAN HEALTH						
MARK LATHROP - MCGILL *Medical genomics*	**39.98**	**5.62**	**36**	**0**	**0**	**5 years**
2012 COMPETITION: BIOINFORMATICS AND COMPUTATIONAL BIOLOGY						
JÉRÔME WALDISPÜHL - MCGILL *McGill • Science games in genomics*	**15.25**	**4.72**	**3**	**10**	**1**	**2.5 years**
MATHIEU BLANCHETTE - MCGILL • *PIATEA, transposable element annotation*	**11.55**	**3.5**	**3**	**7**	**0**	**2.25 years**
ANNE-CLAUDE GINGRAS - SAMUEL LUNENFELD RESEARCH INSTITUTE / MIKE TYERS - UMONTRÉAL • *ProHits: functional proteomics data analysis*	**5.5**	**0**	**5**	**24**	**1**	**2.75 years**
ABC COMPETITION						
THOMAS BUREAU - MCGILL *VEGI (crop improvement)*	**58**	**11**	**22**	**54**	**3**	**5 years**
ADRIAN TSANG - UCONCORDIA *Genozymes (bioproducts and bioprocesses development)*	**314.3**	**35**	**52**	**37**	**13**	**5 years**
PETER FACCHINI -UALBERTA / VINCENT MARTIN-UCONCORDIA *Phytometasyn (synthetic biosystems for the production of high value plant metabolites)*	**38.7**	**0**	**44**	**74**	**27**	**5 years**
RICHARD GOLD - MCGILL *Valgen (value addition through genomics)*	**11**	**0**	**50**	**145**	**0**	**5 years**
2010 COMPETITION: LARGE-SCALE APPLIED RESEARCH PROJECTS						
JOHN MACKAY - ULAVAL / JÖRG BOHLMAN-UCOLOMBIE-BRITANNIQUE *SMarTForest (sustainable forestry)*	**165.8**	**37.5**	**68**	**115**	**0**	**4 years**
B. FRANZ LANG/ MOHAMED HIJRI - UMONTRÉAL *GenoRem (decontaminating soils)*	**154.2**	**55.1**	**25**	**84**	**0**	**4 years**
ENTREPRENEURSHIP PROGRAM - EDUCATION IN GENOMICS						
DENIS J. GARAND - ULAVAL *BEST in Genomics! (optimize transfer of knowledge)*	**14.1**	**2.3**	**0**	**17**	**0**	**3 years**

	NUMBER OF PERSONS EMPLOYED *(person-years*	NUMBER OF SCIENTISTS TRAINED *(person-years)*	NUMBER OF PUBLICATIONS ACCEPTED	NUMBER OF CONFERENCES AS SPEAKER	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS	DURATION OF THE PROJECT
GQ HEALTH COMPETITION						
GREGOR ANDELFINGER - CHU STE-JUSTINE *Congenital heart disease*	9.7	2.4	2	4	1	4 years
GUY A. ROULEAU - CHUM *Bipolar disorders*	12.9	0.2	5	5	0	3 years
GUY SAUVAGEAU - UMONTRÉAL *Acute myeloid leukemia*	28	2.2	7	9	5	3 years
JOHN H. WHITE - MCGILL • *Tuberculosis*	15.8	6.7	5	14	0	3 years
KEN DEWAR - MCGILL • *Digestive problems*	18.1	5.8	3	9	0	3 years
MARK BASIK - LADY DAVIS INSTITUTE *Breast cancer*	36.1	10.5	7	20	0	4.5 years
MICHAEL HALLET - MCGILL • *Breast cancer*	22.3	5	5	5	0	4 years
ALAIN MOREAU - CHU STE-JUSTINE *Diagnostic tools for pediatric scoliosis*	26.6	11.8	4	3	0	4 years
MICHEL G. BERGERON - ULAVAL *Rapid diagnostic tests*	12	1	0	8	1	2 years
MARYAM TABRIZIAN - MCGILL *Portative biosensors*	17.7	6.7	15	19	0	4 years
PAUL GOODYER - INSTITUT DE RECHERCHE DU CUSM •*Cell therapy of cystinosis*	18.1	7.1	1	10	0	3 years
PAVEL HAMET - CHUM • *Type 2 diabetes*	27.4	5.7	0	22	6	3.5 years
GORDON SHORE/ MICHEL L. TREMBLAY - MCGILL *Cancer therapy*	18.3	2.7	0	6	1	3.5 years
COMPETITION - QUÉBEC VERT						
FRANÇOIS BELZILE - ULAVAL *GreenSNPs (environmental genomics)*	5.6	2	4	9	0	2 years
CONNIE LOVEJOY - ULAVAL *CATG (genomics for Artic environment)*	4.2	1.2	0	3	0	1.5 an
VINCENT MARTIN - UCONCORDIA *PAYGE (reducing fuel dependency)*	2.6	0	0	0	0	2 years

	NUMBER OF PERSONS EMPLOYED *(person-years*	NUMBER OF SCIENTISTS TRAINED *(person-years)*	NUMBER OF PUBLICATIONS ACCEPTED	NUMBER OF CONFERENCES AS SPEAKER	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS	DURATION OF THE PROJECT
GQ PILOT PROJECTS COMPETITION						
JAMIE ENGERT - INSTITUT DE RECHERCHE DU CUSM • *Heart disease*	3	0	0	0	0	2 years
JULIE ST-PIERRE - MCGILL • *Breast Cancer*	4.4	1	1	1	0	2 years
PIERRE DRAPEAU/ EDOR KABASHI - UMONTRÉAL *Amyotrophic lateral sclerosis therapeutics*	9.8	6	3	12	1	2 years
ROGER C. LEVESQUE - ULAVAL • *Budworm ecogenomics*	8.5	2	3	15	0	2 years
SARAH KIMMINS - MCGILL • *Infertility*	5.6	3.1	2	9	0	2 years
ZOHA KIBAR - CHU STE-JUSTINE *Neura tube defects*	4.8	0	0	0	0	2 years
COMPETITIONS I & II. HEALTHCOMPETITIONS I & II. HEALTHCOMPETITIONS I & II. HEALTHCOMPETITIONS I & II. HEALTH						
MICHEL G. BERGERON - CHU DE QUÉBEC *Theranostics technologies (diagnostic tests to identify microbes causing infections)*	118	25	25	58	11	3.25 years
DEMING XU - PRIVÉ *Chemogenomics (new treatments for life-threatening fungal infections)*	101	2	8	4	1	3 years
THOMAS J. HUDSON - MCGILL *ARCTIC (colorectal cancer)*	42	6	19	15	9	3.25 years
FRANZ LANG - UMONTRÉAL *PEP Québec (evolution of eurayotic cells and corresponding genes)*	49	21	20	18	0	3.5 years
BUSSEY/MICHNICK - MCGILL *Model organisms (genetic interaction in eukaryotic cells)*	20	4	18	55	0	4 years
JOHN J.M. BERGERON - MCGILL *Proteomics (function and structure of genes and proteins)*	174	67	42	125	7	4 years
FERNAND LABRIE - ULAVAL *Atlas (profiles of steroid action)*	347	120	49	29	2	5 years
BARTHA MARIA KNOPPERS - MCGILL *GE3LS (genomics and society)*	38	20	83	153	0	4 years
FATHEY SARHAN - UQAM *Abiotic Stress Québec (improve agricultural productivity)*	82	28	11	17	0	4 years
THOMAS J. HUDSON - MCGILL • *Regulatory genetics (identificaion of regulatory polymorphisms in the human genome)*	117	27	16	51	6	4 years
RAFICK-PIERRE SÉKALY - UMONTRÉAL *S2K (immune response)*	194	79	17	150	6	4 years
MARIO FILLION - MCGILL *IGWH (women's health)*	36	5	1	10	4	3 years

	NUMBER OF PERSONS EMPLOYED *(person-years*	NUMBER OF SCIENTISTS TRAINED *(person-years)*	NUMBER OF PUBLICATIONS ACCEPTED	NUMBER OF CONFERENCES AS SPEAKER	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS	DURATION OF THE PROJECT
COMPETITION III, INTERNATIONAL CONSORTIUM INITIATIVE, PRIVAC, TECHNOLOGY DEVELOPMENT						
SHERIF ABOU ELELA - USHERBROOKE *MoNa (genome wide analysis of gene function)*	51	8	6	9	2	3 years
ADRIAN TSANG - UCONCORDIA *Fungal enzymes (environmental remediation)*	167	69	16	22	8	3 years
BENOIT COULOMBE - UMONTRÉAL *Regulatory networks (decode genetic information)*	189	63	15	111	0	3.5 years
JOHN MACKAY - ULAVAL *Arborea I (health of trees)*	98	31	23	63	2	3.5 years
THOMAS J. HUDSON - MCGILL *HapMap (genetic research)*	34	2	14	87	1	3 years
EMIL SKAMENE - MCGILL *Congenic mice (direct complex traits relevant tu human health)*	60	13	2	11	3	4.25 years
GUY ROULEAU - UMONTRÉAL *Ionic channels (hereditary neurological disorder)*	40	5	0	16	3	4.25 years
TERRY ROEMER - PRIVÉ *Candida albicans (antifungal drug discovery)*	51	0	2	3	3	3 years
BARRY POSNER/ROB SLADEK - MCGILL *Type 2 diabetes*	91	23	25	35	6	5.5 years
BARTHA MARIA KNOPPERS - MCGILL *GPH (genomics and public health*	5	4	22	47	0	3 years

	NUMBER OF PERSONS EMPLOYED *(person-years*	NUMBER OF SCIENTISTS TRAINED *(person-years)*	NUMBER OF PUBLICATIONS ACCEPTED	NUMBER OF CONFERENCES AS SPEAKER	NUMBER OF DECLARATIONS OF INVENTION OR PATENTS	DURATION OF THE PROJECT
COMPETITION III, INTERNATIONAL CONSORTIUM INITIATIVE, PRIVAC, TECHNOLOGY DEVELOPMENT						
SHERIF ABOU ELELA - USHERBROOKE *FAESI (alternative splicing)*	101.5	10.8	11	28	3	5.25 years
KEN DEWAR - MCGILL *Vervet monkey (neuro-development and neurological deterioration)*	18.3	2	3	4	0	4.75 years
TOMI M. PASTINEN - MCGILL *GRID (gene regulators)*	213	51.5	84	42	2	4.5 years
GUY A. ROULEAU - UMONTRÉAL *S2D (brain diseases)*	86	12	14	41	1	5 years
JEAN-CLAUDE TARDIF - ICM *Pharmacogenomics (cardiovascular disease)*	346	41	15	87	0	4 years
JOHN MACKAY - ULAVAL *Arborea II (improve productivity of forests products)*	186	66.6	49	95	0	5 years
BARTHA MARIA KNOPPERS/ THOMAS J. HUDSON - MCGILL *P3G/CaG (populations genomics)*	33.5	57	35	54	0	3 years
DANIEL LAMARRE/ SYLVAIN MELOCHE - IRIC *RNA platform (new targeted therapies for cancer)*	16.8	0	0	3	0	2 years
RAFICK-PIERRE SÉKALY - UMONTRÉAL *NIML platform (vaccines et immunotherapies)*	18	3	4	5	2	2 years
MICHEL G. BERGERON - CHUQ *GPOCT (infectiology)*	45	2	9	18	1	2.25 years
MICHAEL PHILLIPS/ JEAN-CLAUDE TARDIF - ICM *Via-PGX (cardiovascular pharmacogenomics*	17.5	3.6	4	44	0	2.5 years
MARYAM TABRIZIAN - MCGILL *DevTab (biomarkers discovery and validation)*	35.3	15.2	34	13	0	2 years
RAFICK-PIERRE SÉKALY RYAN BRINKMAN - UMONTRÉAL - BCCA *DevSek (immune system)*	6	1	2	4	0	2 years
TOTAL COMPLETED PROJECTS	4,431.9	1,125.5	1,126	2,319	143	

CORPORATE INFORMATION

For more information, please contact Louise Thibault, Senior Consultant, Events and Special Projects at 514 398-0668 ext. 232 or by e-mail at lthibault@genomequebec.com

Thanks to our partners

GenomeCanada

Économie, Science et Innovation Québec

HEAD OFFICE GÉNOME QUÉBEC

630, René-Lévesque Blvd West,
Suite 2660,
Montréal (QC) H3B 1S6
514 398-0668
Fax: 514 398-0883
gqinfo@genomequebec.com
genomequebec.com

AUDITORS KPMG S.R.L./S.E.N.C.R.L

600, de Maisonneuve Blvd West,
Suite 1500
Montréal (QC) H3A 0A3
kpmg.ca

LEGAL ADVISER

Me Jean Brunet
Stein Monast, S.E.N.C.R.L.
70, rue Dalhousie, Suite 300,
Québec (QC) G1K 4B2
steinmonast.ca

GÉNOME CANADA

150, rue Metcalfe, Suite 2100,
Ottawa (ON) K2P 1P1
genomecanada.ca

MINISTÈRE DE L'ÉCONOMIE, DE LA SCIENCE ET DE L'INNOVATION

710, place D'Youville, 3rd floor,
Québec (QC) G1R 4Y4
economie.gouv.qc.ca

MCGILL UNIVERSITY AND GÉNOME QUEBEC INNOVATION CENTRE

740, Docteur-Penfield Avenue,
Montréal (QC) H3A 1A4
514 398-7211
Fax: 514 398-1790
infoservices@genomequebec.com
gqinnovationcentre.com

GÉNOME QUÉBEC AND CENTRE HOSPITALIER AFFILIÉ UNIVERSITAIRE RÉGIONAL DE CHICOUTIMI BIOBANK

305, Saint-Vallier Street
Chicoutimi (QC) G7H 5H6
514 398-7211
infoservices@genomequebec.com

CHU SAINTE-JUSTINE AND GÉNOME QUÉBEC INTEGRATED CLINICAL GENOMIC CENTRE IN PEDIATRICS

3175, Ch. de la Côte-Sainte-Catherine
Montréal (QC) H3T 1C5
514 345-4931, poste 6193
rallard@genomequebec.com

GenomeQuébec

630, boul. René-Lévesque Ouest,
bureau 2660
Montréal (Québec) H3B 1S6

genomequebec.com

GenomeQc

GenomeQuebec